APPENDIX 12 Antivirals publications, 2010–2011 1. 2009. [Black triangle down] Tamiflu – the wrong message? Drug Ther.Bull. 47:97. doi:47/9/97 [pii];10.1136/dtb.2009.08.0034 [doi]. 2. 2009. A caution about giving Tamiflu to children. Child Health Alert. 27:4–5. 3. 2009. Antiviral drugs for influenza. Med.Lett.Drugs Ther. 51:89–92. 4. 2009. Campus response to novel influenza H1N1. J.Am.Coll.Health 58:281–289. doi:U6265414166J437M [pii];10.1080/07448480903482510 [doi]. 5. 2009. Case management for influenza. J.Indian Med.Assoc. 107:528–530. 6. 2009. Epidemiology of seasonal, avian and pandemic influenza. J.Indian Med.Assoc. 107:506–507. 7. 2009. Foreword: this issue of the Seton Hall Law Review presents contributions to Preparing for Pharmaceutical Response to Pandemic Influenza, a two-day Symposium held at Seton hall University School of Law in the fall of 2008. Seton.Hall.Law Rev. 39:1103–1109. 8. 2009. Pandemic preparedness. Alta.RN. 65:20–27. 9. 2009. Update on oseltamivir-resistant pandemic A (H1N1) 10. 2009 influenza virus: January 2010. Wkly.Epidemiol.Rec. 85:37–40. 11. 2010. [Technical report on the 2009 influenza A (H1N1) pandemic]. An.Pediatr.(Barc.) 72:81–35. doi:S1695-4033(09)00614-6 [pii];10.1016/j.anpedi.2009.11.002 [doi]. 12. 2010. [Treatment with antiviral agents]. An.Pediatr.(Barc.) 72:81–85. doi:S1695-4033(09)00621-3 [pii];10.1016/j.anpedi.2009.11.009 [doi]. 13. 2010. 2009 pandemic influenza A (H1N1) in pregnant women requiring intensive care – New York City, 2009. MMWR Morb.Mortal.Wkly.Rep. 59:321–326. doi:mm5911a1 [pii]. 14. 2010. A pandemic of hindsight? Nature 465:985. doi:465985a [pii];10.1038/465985a [doi]. 15. 2010. Fatal H1N1 infection in an HIV positive woman. Negative flu tests, HIV infection delay treatment. AIDS Alert. 25:9–10. 16. 2010. Influenza activity – United States and worldwide, June 13–September 25, 2010. MMWR Morb. Mortal.Wkly.Rep. 59:1270–1273. doi:mm5939a3 [pii]. 17. 2010. Outbreak of 2009 pandemic influenza A (H1N1) on a Peruvian Navy ship – June–July 2009. MMWR Morb.Mortal.Wkly.Rep. 59:162–165. doi:mm5906a3 [pii]. 18. 2010. Outbreaks of 2009 pandemic influenza A (H1N1) among long-term-care facility residents – three states, 2009. MMWR Morb.Mortal.Wkly.Rep. 59:74–77. doi:mm5903a3 [pii]. 19. 2010. Patient education series. Seasonal influenza (the flu). Nursing. 40:33. doi:10.1097/01. NURSE.0000387238.05776.38 [doi];00152193-201009000-00011 [pii]. 20. 2010. Patient information. Influenza. Am.Fam.Physician 82:1097. doi:p722 [pii]. 211 WHO PUBLIC HEALTH RESEARCH AGENDA FOR INFLUENZA 21. 2010. Patients hospitalized with 2009 pandemic influenza A (H1N1) – New York City, May 2009. MMWR Morb.Mortal.Wkly.Rep. 58:1436–1440. doi:mm5851a2 [pii]. 22. 2010. Update: influenza activity – United States, 2009–10 season. MMWR Morb.Mortal.Wkly.Rep. 59:901–908. doi:mm5929a2 [pii]. 23. 2010. Update: influenza activity – United States, October 3–December 11, 2010. MMWR Morb. Mortal.Wkly.Rep. 59:1651–1655. doi:mm5950a4 [pii]. 24. 2011. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture]. Antibiot.Khimioter. 56:3–9. 25. 2011. Antiviral drugs for influenza. Med.Lett.Drugs Ther. 53:1–3. 26. 2011. Infectious disease. Antiviral agents for the treatment and chemoprophylaxis of influenza. Ann. Emerg.Med. 58:299–303. doi:S0196-0644(11)01304-7 [pii];10.1016/j.annemergmed.2011.07.007 [doi]. 27. 2011. Recommended composition of influenza virus vaccines for use in the 2011–2012 northern hemisphere influenza season. Wkly.Epidemiol.Rec. 86:86–90. 28. 2011. Update: influenza activity – United States, October 3, 2010–February 5, 2011. MMWR Morb. Mortal.Wkly.Rep. 60:175–181. doi:mm6006a4 [pii]. 29. Aardema, H., J. E. Tulleken, R. J. van den Biggelaar, B. A. Wolters, C. M. de Jager, C. A. Boucher, and A. Riezebos-Brilman. 2010. [Fatal pneumonitis due to oseltamivir-resistant new influenza A(H1N1) in the case of an intensive care patient]. Ned.Tijdschr.Geneeskd. 154:A1634. 30. Abdel-Rahman, S. M., J. G. Newland, and G. L. Kearns. 2011. Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. Paediatr.Drugs 13:19–31. doi:3 [pii];10.2165/11536950-000000000-00000 [doi]. 31. Abdo, A., C. Alfonso, G. Diaz, M. Wilford, M. Rocha, and N. Verdecia. 2011. Fatal 2009 pandemic influenza A (H1N1) in a bone marrow transplant recipient. J.Infect.Dev.Ctries. 5:132–137. 32. Abed, Y., P. Simon, and G. Boivin. 2010. Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation. Antimicrob.Agents Chemother. 54:2819–2822. doi:AAC.01681-09 [pii];10.1128/ AAC.01681-09 [doi]. 33. Accinelli, C., M. L. Sacca, J. Fick, M. Mencarelli, R. Lindberg, and B. Olsen. 2010. Dissipation and removal of oseltamivir (Tamiflu) in different aquatic environments. Chemosphere 79:891–897. doi:S0045-6535(10)00168-2 [pii];10.1016/j.chemosphere.2010.02.022 [doi]. 34. Acosta, E. P. and D. W. Kimberlin. 2010. Determination of appropriate dosing of influenza drugs in pediatric patients. Clin.Pharmacol.Ther. 88:704–707. doi:clpt2010173 [pii];10.1038/clpt.2010.173 [doi]. 35. Acosta, E. P., P. Jester, P. Gal, J. Wimmer, J. Wade, R. J. Whitley, and D. W. Kimberlin. 2010. Oseltamivir dosing for influenza infection in premature neonates. J.Infect.Dis. 202:563–566. doi:10.1086/654930 [doi]. 36. Adalja, A. 2009. Optimization of antiviral prescribing for influenza. J.Hosp.Med. 4:E28. doi:10.1002/ jhm.538 [doi]. 37. Adalja, A. A. 2010. Hematemesis in a 2009 H1N1 influenza patient. Am.J.Emerg.Med. 28:846–4. doi:S0735-6757(09)00636-6 [pii];10.1016/j.ajem.2009.12.012 [doi]. 38. Adams, S. and C. Sandrock. 2010. Avian influenza: update. Med.Princ.Pract. 19:421–432. doi:000320299 [pii];10.1159/000320299 [doi]. 212 BIANNUAL PROGRESS REVIEW AND REPORT 2010–2011 39. Adisasmito, W., B. M. Hunter, R. Krumkamp, K. Latief, J. W. Rudge, P. Hanvoravongchai, and R. J. Coker. 2011. Pandemic Influenza and Health System Resource Gaps in Bali: An Analysis Through a Resource Transmission Dynamics Model. Asia Pac.J.Public Health. doi:1010539511421365 [pii];10.1177/1010539511421365 [doi]. 40. Adisasmito, W., P. K. Chan, N. Lee, A. F. Oner, V. Gasimov, F. Aghayev, M. Zaman, E. Bamgboye, N. Dogan, R. Coker, K. Starzyk, N. A. Dreyer, and S. Toovey. 2010. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J.Infect.Dis. 202:1154– 1160. doi:10.1086/656316 [doi]. 41. Adisasmito, W., P. K. Chan, N. Lee, A. F. Oner, V. Gasimov, M. Zaman, E. Bamgboye, N. Dogan, K. Starzyk, N. A. Dreyer, and S. Toovey. 2011. Strengthening observational evidence for antiviral effectiveness in influenza A (H5N1). J.Infect.Dis. 204:810–811. doi:jir398 [pii];10.1093/infdis/jir398 [doi]. 42. Aeffner, F., Z. P. Traylor, E. N. Yu, and I. C. Davis. 2011. Double-stranded RNA induces similar pulmonary dysfunction to respiratory syncytial virus in BALB/c mice. Am.J.Physiol Lung Cell Mol. Physiol 301:L99–L109. doi:ajplung.00398.2010 [pii];10.1152/ajplung.00398.2010 [doi]. 43. Agrati, C., C. Gioia, E. Lalle, E. Cimini, C. Castilletti, O. Armignacco, F. N. Lauria, F. Ferraro, M. Antonini, G. Ippolito, M. R. Capobianchi, and F. Martini. 2010. Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J.Infect.Dis. 202:681–689. doi:10.1086/655469 [doi]. 44. Agrawal, A. S., M. Sarkar, S. Ghosh, T. Roy, S. Chakrabarti, R. Lal, A. C. Mishra, M. S. Chadha, and M. Chawla-Sarkar. 2010. Genetic characterization of circulating seasonal Influenza A viruses (2005– 2009) revealed introduction of oseltamivir resistant H1N1 strains during 2009 in eastern India. Infect. Genet.Evol. 10:1188–1198. doi:S1567-1348(10)00207-8 [pii];10.1016/j.meegid.2010.07.019 [doi]. 45. Agrawal, R., P. V. Rewatkar, G. R. Kokil, A. Verma, and A. Kalra. 2010. Oseltamivir: a first line defense against swine flu. Med.Chem. 6:247–251. doi:BSP/MC/Epub/052 [pii]. 46. Ai, H., F. Zheng, C. Zhu, T. Sun, L. Zhang, X. Liu, X. Li, G. Zhu, and H. Liu. 2010. Discovery of novel influenza inhibitors targeting the interaction of dsRNA with the NS1 protein by structure-based virtual screening. Int.J.Bioinform.Res.Appl. 6:449–460. doi:32Q1497545044537 [pii]. 47. Ainai, A., T. Ichinohe, S. Tamura, T. Kurata, T. Sata, M. Tashiro, and H. Hasegawa. 2010. Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J.Med.Virol. 82:476–484. doi:10.1002/jmv.21694 [doi]. 48. Akyuz, S., A. Yilmaz, M. Bulbul, O. Erdogan, R. Renda, and G. Demircin. 2011. Do immunosupressive patients really have a severe outcome with H1N1 virus infection? J.Trop.Pediatr. 57:129–131. doi:fmq054 [pii];10.1093/tropej/fmq054 [doi]. 49. Al Aklabi, M. M., J. G. Weinkauf, A. Humar, and N. Ghorpade. 2010. Successful bilateral lung transplantation in a patient with end-stage lung disease and positive novel influenza virus (H1N1). J.Heart Lung Transplant. 29:898–899. doi:S1053-2498(10)00274-3 [pii];10.1016/j. healun.2010.04.017 [doi]. 50. Al-Baghli, F. and W. Al-Ateeqi. 2011. Encephalitis-associated pandemic A (H1N1) 2009 in a Kuwaiti girl. Med.Princ.Pract. 20:191–195. doi:000321276 [pii];10.1159/000321276 [doi]. 51. Albohy, A., S.